What are the recommended treatment options for hot flashes in menopausal women, including hormonal and non‑hormonal therapies and considerations for contraindications?

Treatment of Hot Flashes in Menopausal Women

For moderate to severe hot flashes, start with venlafaxine 37.5 mg daily, increasing to 75 mg after one week, or gabapentin 900 mg at bedtime if the patient has sleep disturbance, is on multiple medications, or is taking tamoxifen. 1, 2

First-Line Nonhormonal Pharmacologic Options

The National Comprehensive Cancer Network and American College of Obstetricians and Gynecologists recommend nonhormonal pharmacologic treatments as first-line therapy for menopausal hot flashes. 1, 2

Venlafaxine (SNRI)

• Start at 37.5 mg daily, increase to 75 mg daily after 1 week if greater symptom control is needed 1, 2
• Reduces hot flash scores by 37-61% depending on dose 1, 2
• Rapid onset of action (within 1 week) 3, 2
• Preferred by 68% of patients over gabapentin despite similar efficacy 1, 2
• Common side effects include dry mouth, decreased appetite, fatigue, nausea, and constipation 2
• Requires gradual taper on discontinuation to avoid withdrawal syndrome 1
• Review efficacy at 2-4 weeks; if ineffective or poorly tolerated, switch to another agent 1, 2

Gabapentin (Anticonvulsant)

• Dose: 900 mg/day, preferably taken at bedtime 3, 1, 2
• Reduces hot flash severity by 46% compared to 15% with placebo 3, 1, 2
• Particularly useful when taken at bedtime for patients whose sleep is disturbed by hot flashes 3, 1
• Has no known drug interactions and no absolute contraindications, making it safer than SSRIs/SNRIs in complex medication regimens 1
• Side effects (dizziness, drowsiness, unsteadiness) affect up to 20% but markedly improve after the first week and largely resolve by week 4 3, 1
• Review efficacy at 4-6 weeks 1
• Consider as first-line if sexual dysfunction is a concern or if patient is taking tamoxifen 1, 2

Paroxetine (SSRI)

• Dose: 7.5-12.5 mg daily (controlled release) or 10-20 mg daily (immediate release) 3, 2
• Reduces hot flash frequency, severity, and nighttime awakenings by 62-65% 1, 2
• CRITICAL WARNING: Must be avoided in women taking tamoxifen due to CYP2D6 inhibition, which reduces conversion of tamoxifen to its active metabolite 1, 2
• Fluoxetine should also be avoided in tamoxifen users for the same reason 1
• Use venlafaxine, citalopram, or gabapentin instead in tamoxifen users 1

Important Contraindications for SSRIs/SNRIs

• Contraindicated in women taking monoamine oxidase inhibitors 3
• Should be avoided in women with bipolar disorder due to risk of inducing mania 3
• If no response in 4 weeks, the treatment is unlikely to be effective 3

Second-Line Nonhormonal Option

Clonidine (Alpha-Agonist)

• Dose: 0.1 mg/day oral or transdermal 3, 2
• Reduces hot flashes by up to 46% 3, 2
• May have slower onset than venlafaxine but is often better tolerated 1
• Common side effects include dry mouth and insomnia or drowsiness 3, 2
• Doses used for hot flashes do not appear to affect blood pressure 3
• Consider for mild to moderate hot flashes or for those who wish to avoid other agents 3, 2

Comparative Efficacy (Mean Reduction in Daily Hot Flashes vs. Placebo)

• Gabapentin: 2.05 fewer hot flashes per day 3, 1
• SSRI/SNRI: 1.13 fewer hot flashes per day 3, 1
• Clonidine: 0.95 fewer hot flashes per day 3, 1

Nonpharmacologic Approaches

Lifestyle Modifications

• Weight loss of ≥10% of body weight may eliminate hot flash symptoms entirely 1, 2
• Smoking cessation improves frequency and severity of hot flashes 1, 2
• Limiting alcohol intake when it acts as a trigger 1
• Environmental adjustments: dress in layers, maintain cool room temperatures, wear natural fibers, use cold packs intermittently 1
• Avoid identified triggers (spicy food, hairdryers, anxiety) 1
• Keep a hot flash diary to identify personal triggers 1

Mind-Body Interventions

• Paced respiration training (structured breathing exercises for 20 minutes daily) shows significant benefit 3, 1
• Structured relaxation techniques for 20 minutes daily show significant beneficial effect 3, 1
• Hypnosis showed a 59% decrease in daily hot flashes and significant improvement in quality of life measures 3
• Cognitive behavioral therapy (CBT) reduces the perceived burden of hot flashes 1, 2
• Yoga may improve quality of life associated with menopause 1, 2

Acupuncture

• Safe and effective, with some studies showing equivalence or superiority to venlafaxine or gabapentin 1, 2
• Breast cancer survivors with prior axillary surgery should avoid the affected arm 3

Hormonal Therapy (When Nonhormonal Options Fail)

Menopausal Hormone Therapy (MHT)

• Most effective treatment, reducing hot flashes by approximately 75-90% 1, 4
• Transdermal estrogen formulations are strongly preferred over oral preparations due to lower rates of venous thromboembolism and stroke 1
• Use the lowest effective dose for the shortest duration possible 1
• Women with intact uterus require progestin to prevent endometrial hyperplasia 1
• Micronized progestin may be preferred over medroxyprogesterone acetate due to lower rates of VTE and breast cancer risk 1

Ideal Candidates for MHT

• Women younger than 60 years 1
• Within 10 years of menopause onset 1
• No elevated risk for cardiovascular disease, stroke, or breast cancer 1

Absolute Contraindications to MHT

• History of hormonally mediated cancers (breast, endometrial) 1
• Abnormal vaginal bleeding 1
• Active or recent history of thromboembolic events 1
• Pregnancy 1
• Active liver disease 1

Relative Contraindications to MHT

• Coronary heart disease 1
• Hypertension 1
• Current smokers 1
• Increased genetic cancer risk 1

Important MHT Risks

• Combined estrogen/progestogen therapy increases breast cancer risk when used for more than 3-5 years 1
• Increases risk of stroke and venous thromboembolism 1
• Oral estrogen increases stroke risk, especially in women ≥60 years or >10 years after menopause 1

Special Population: Breast Cancer Survivors

Treatment Hierarchy

• Avoid estrogen and tibolone due to potential increased recurrence risk 1
• First-line: venlafaxine, gabapentin, or citalopram 1
• Avoid paroxetine if on tamoxifen 1
• Consider switching from aromatase inhibitor to tamoxifen or vice versa if hot flashes are severe 1
• For women with advanced breast cancer or severe symptoms affecting quality of life, estrogen may be considered after fully informed discussion of risks 1

Ineffective or Unsafe Therapies to Avoid

• Black cohosh: no efficacy in randomized trials and reports of liver failure 1
• Multibotanicals with soy: worsened symptoms in randomized trials 1
• Vitamin E 800 IU daily: limited efficacy, and doses >400 IU/day are linked to increased all-cause mortality 1

Treatment Algorithm

For Moderate to Severe Hot Flashes:

1. Start venlafaxine 37.5 mg daily, increase to 75 mg after 1 week 1, 2
   • OR gabapentin 900 mg at bedtime if sleep disturbance, multiple medications, or on tamoxifen 1
2. Review efficacy at 2-4 weeks for SSRIs/SNRIs or 4-6 weeks for gabapentin 1
3. If ineffective or poorly tolerated, switch to the alternative first-line agent 3, 1
4. If both fail, consider clonidine 0.1 mg/day 2
5. If all nonhormonal options fail and no contraindications exist, consider transdermal estrogen 1

For Mild to Moderate Hot Flashes:

1. Lifestyle modifications: weight loss ≥10% if overweight, smoking cessation, limit alcohol 1, 2
2. Environmental adjustments and trigger avoidance 1
3. Consider paced respiration training, CBT, or acupuncture 1, 2
4. If inadequate, proceed to pharmacologic options as above 2

Important Clinical Pearls

• Recognize the robust placebo response (up to 70% in some studies) when evaluating treatment efficacy 3, 1
• Many hot flashes improve spontaneously over time with ongoing treatment 1
• Do not screen patients for CYP2D6 despite theoretical concerns about SSRI-tamoxifen interactions, as negative impact on breast cancer outcomes has not been conclusively demonstrated 1
• In elderly patients, start with lower doses and titrate slowly to minimize side effects 2
• Monitor for fall risk when using medications that may cause dizziness or drowsiness, such as gabapentin 2